

Title (en)  
NOVEL QUATERNARY AMMONIUM SALTS, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Title (de)  
NEUE QUARTÄRE AMMONIUMSALZE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE ENTHALTENDE ARZNEIMITTEL.

Title (fr)  
NOUVEAUX SELS D'AMMONIUM QUATERNAIRE, LEURS PROCÉDES D'OBTENTION ET LES COMPOSITIONS PHARMACEUTIQUES EN RENFERMANT.

Publication  
**EP 0538436 A1 19930428 (FR)**

Application  
**EP 92910049 A 19920410**

Priority  
FR 9105693 A 19910510

Abstract (en)  
[origin: WO9220646A1] The invention relates to organic chemistry and more especially to therapeutic chemistry. It concerns, in particular, novel quaternary ammonium salts of general formula (I), in which Hal is a halogen atom other than fluorine, R and R<sup>1</sup>?, the same or different, are lower alkyl radicals, n is an integer between 2 and 16, Z is an alkenyl radical having up to 3 carbon atoms, a carboxyl or represents the OR<sup>2</sup>? group in which R<sup>2</sup>? is hydrogen, a lower alkyl radical, an acyl residue, a tocol radical, a sterol radical or a carboxamide chain and A is a hydroxyl or a mineral or organic acid anion. The compounds according to the invention are the active ingredients in anti-tumoral and/or immunosuppressant pharmaceutical compositions.

Abstract (fr)  
L'invention se rapporte au domaine de la chimie organique et plus particulièrement à celui de la chimie thérapeutique. Elle concerne plus particulièrement de nouveaux sels d'ammonium quaternaire de formule générale (I), dans laquelle Hal est un atome d'halogène autre que le fluor, R et R<sup>1</sup>, identiques ou différents, sont des radicaux alcyle inférieur, n est un nombre entier variant de 2 à 16, Z est un radical alcényle ayant jusqu'à 3 atomes de carbone, un carboxyle ou le groupe OR<sup>2</sup> dans lequel R<sup>2</sup> est de l'hydrogène, un radical alcoyle inférieur, un reste acyle, un radical tocol, un radical stérolique ou une chaîne carboxamide et A est un hydroxyle ou l'anion d'un acide minéral ou organique. Les composés selon l'invention sont les principes actifs de compositions pharmaceutiques à action anti-tumorale et/ou immunosuppressive.

IPC 1-7  
**A61K 31/14; A61K 31/35; A61K 31/59; C07C 211/63; C07C 215/90; C07C 229/12; C07D 239/54; C07D 239/545**

IPC 8 full level  
**A61K 31/35** (2006.01); **A61K 31/352** (2006.01); **A61K 31/505** (2006.01); **A61K 31/575** (2006.01); **A61K 31/70** (2006.01); **A61K 31/7042** (2006.01); **A61K 31/7052** (2006.01); **A61K 31/7064** (2006.01); **A61K 31/7072** (2006.01); **A61K 31/7076** (2006.01); **A61P 17/00** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/06** (2006.01); **C07C 211/63** (2006.01); **C07C 215/40** (2006.01); **C07C 217/08** (2006.01); **C07C 219/04** (2006.01); **C07C 229/04** (2006.01); **C07C 229/12** (2006.01); **C07C 237/04** (2006.01); **C07D 239/52** (2006.01); **C07D 239/54** (2006.01); **C07D 311/72** (2006.01); **C07D 473/32** (2006.01); **C07H 19/06** (2006.01); **C07H 19/16** (2006.01); **C07J 41/00** (2006.01)

CPC (source: EP US)  
**A61P 17/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **C07C 211/63** (2013.01 - EP US); **C07C 215/40** (2013.01 - EP US); **C07C 229/12** (2013.01 - EP US); **C07D 239/54** (2013.01 - EP US)

Citation (search report)  
See references of WO 9220646A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

DOCDB simple family (publication)  
**WO 9220646 A1 19921126**; EP 0538436 A1 19930428; FR 2676224 A1 19921113; FR 2676224 B1 19960802; JP H06500340 A 19940113; US 5399590 A 19950321

DOCDB simple family (application)  
**FR 9200317 W 19920410**; EP 92910049 A 19920410; FR 9105693 A 19910510; JP 50951292 A 19920410; US 96983293 A 19930114